Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11072555 | 1.00 | CYP1A2 (0.69) | CYP1A2POLBAMY1AALDH1A1TDP1 | |
| SCHEMBL3737258 | 0.87 | CYP1A2 (0.64) | CYP1A2POLBAMY1AALDH1A1TDP1 | |
| SCHEMBL3737256 | 0.87 | CYP1A2 (0.64) | CYP1A2POLBAMY1AALDH1A1TDP1 | |
| SCHEMBL6292292 | 0.84 | CYP1A2 (0.75) | CYP1A2AMY1AALDH1A1TDP1CYP3A4 | |
| SCHEMBL18982479 | 0.84 | CYP1A2 (0.53) | CYP1A2POLBALDH1A1TDP1CYP3A4 | |
| SCHEMBL17353527 | 0.84 | CYP1A2 (0.53) | CYP1A2POLBALDH1A1TDP1CYP3A4 | |
| SCHEMBL28551175 | 0.83 | MAOA (0.49) | CYP1A2POLBALDH1A1MAPTMEN1 | |
| SCHEMBL6037267 | 0.83 | CYP1A2 (0.73) | CYP1A2AMY1AALDH1A1TDP1CYP3A4 | |
| SCHEMBL16619742 | 0.81 | CYP1A2 (0.47) | CYP1A2POLBALDH1A1TDP1MAPT | |
| SCHEMBL865986 | 0.81 | CYP1A2 (1.00) | CYP1A2ALDH1A1TDP1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4400493-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-117980293-A | Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023036289-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-03-16 | — | — | WO | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-4426536-A | Synthesis of phenylacetic acid esters | ELI LILLY AND COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0098058-A1 | Synthesis of phenylacetic acid esters | ELI LILLY AND COMPANY (US) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | ENPP1, ENPP2, ENPP3 | CYP1A2 4427/4885POLB 2967/4885AMY1A 2406/4885 |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | CYP1A2 3208/4885POLB 4799/4885AMY1A 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.